The first study of immune checkpoint inhibition in men with germ cell tumours found no clinically meaningful activity of the programmed cell death protein 1 inhibitor pembrolizumab. Treatment with a median of two doses (range 1–8) in 12 patients with refractory nonseminoma resulted in no partial or complete responses. Two patients had radiographically stable disease for 19 weeks and 28 weeks but displayed a continued increase in α-fetoprotein levels.
References
Adra, N. et al. Phase II trial of pembrolizumab in patients with platinum refractory germ cell tumors: a Hoosier Cancer Research Network Study GU14-206. Ann. Oncol. http://dx.doi.org/10.1093/annonc/mdx680 (2017)
Rights and permissions
About this article
Cite this article
Thoma, C. No activity of pembrolizumab in phase II trial. Nat Rev Urol 14, 700 (2017). https://doi.org/10.1038/nrurol.2017.194
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2017.194